Supplementary Table definition

Supplementary Table. 5: TRIPOD reporting scores for articles published after TRIPOD statement in journals that require adherence to the TRIPOD statement and journals that do not require to the adherence statement Supplementary Table 6: Percentage articles reporting TRIPOD items in supplementary material TRIPOD item Supplement % TRIPOD item Supplement % Supplementary figure 1: Average overall TRIPOD reporting levels in percentage per year 202 Supplementary Table 7: Performance measures and missing data in all studies Calibration Discrimination Classification Clinical usefulness Overall performance Missing data reporting Type and reason of missing data Missing data handling 203 Supplementary Table 8: Model development and presentation Sample per candidate predictor 204 Model Type Predictor Selection Model building Model building thresholds Internal validation Model presentation Supplementary Table 9: External validation and updating Before 2015 (n=18) Number (%) After 2016 (n=26) Number (%) External validation Model updating Article selection Search strategy:
View Source
Supplementary Table. S1: Same as Table 1, but for scenarios considered compatible with 1.5°C and 2°C warming in the 5th assessment report of IPCC (▇▇▇▇▇▇ et al. 2014, ▇▇▇▇▇▇ et al. 2015), including projections of changes in regional climate associated with resulting global temperature levels derived following previous studies (Seneviratne et al. 2016, ▇▇▇▇▇▇▇▇▇▇▇▇ et al. 2017) SCEN_1p5C Emissions pathways currently considered in line with keeping warming below 1.5°C in 2100 with 66% chance (allowing for a higher peak in temperature earlier) SCEN_2C Emissions pathways currently considered in line with keeping warming below 2°C during the entire 21st century with 66% chance “probable” (66th percentile) outcomea “worst-case” 10% (90th percentile) outcomeb “probable” (66th percentile) outcomea “worst-case” 10% (90th percentile) outcomeb General characteristics of pathway Overshoot 1.5°C in 21st century with >50% likelihoodc Yes (8/8) Yes (8/8) Yes (60/60) Yes (60/60) Overshoot 2°C in 21st century with >50% likelihood No (0/8) Yes (4/8) No (0/60) Yes (60/60) Cumulative CO2 emissions up to peak warming (relative to 2016)d 510 (490, 560) 470 (410, 520) 930 (790, 1050) 900 (750, 1040) Cumulative CO2 emissions up to 2100 (relative to 2016)d [GtCO2] -40 (-100, 10) 850 (520, 1000) Global GHG emissions in 2030d [GtCO2 y-1] 19 (17, 21) 28 (23, 32) Years of global net zero CO2 emissionsd 2061 (2061, 2063) 2084 (2079, 2086) Warming in the Arctice (TNnf) [°C] 4.75 °C (4.09, 5.44) 5.90 °C (4.97, 6.85) 5.63 °C (4.68, 6.59) 6.97 °C (6.13, 8.38) Warming in the contiguous United Statese (TXxf) [°C] 2.39 °C (1.90, 2.84) 2.97 °C (2.36, 3.40) 2.77 °C (2.20, 3.30) 3.51 °C (3.05, 4.11) Warming in Central Brazile (TXxf) [°C] 2.55 °C (2.12, 2.97) 3.12 °C (2.66, 3.76) 2.96 °C (2.58, 3.55) 3.66 °C (3.31, 4.21) Drying in the Mediterranean regione [stdf] (-1: dry; -2: severely dry; -3: very severely dry) -1.00 (-2.12, -0.39) -1.25 (-2.21, -0.51) -1.11 (-2.18, -0.51) -1.36 (-2.93, -0.69) Increase in heavy precipitation eventsf in Southern Asiae [%] 9.78 % (6.52, 13.63) 11.56 % (7.04, 18.50) 10.27 % (6.50, 17.40) 16.74 % (9.60, 23.44) Warming in the Arcticg (TNnf) [°C] 4.07 °C (3.53, 4.72) 5.37 °C (4.60, 6.40) 5.37 °C (4.46, 6.38) 6.86 °C (5.83, 8.24) Warming in the contiguous United Statesg (TXxf) [°C] 2.00 °C (1.60, 2.48) 2.62 °C (2.17, 3.23) 2.62 °C (2.07, 3.24) 3.37 °C (2.88, 4.03) Warming in Central Brazilg (TXxf) [°C] 2.20 °C (1.95, 2.58) 2.88 °C (2.46, 3.48) 2.88 °C (2.43, 3.47) 3.57 °C (3.20, 4.18) Dry...
View Source
Supplementary Table. 5: Regression equations developed for the prediction of MET values based on acceleration outputs from GENEActiv (GA) and ActiGraph (AG). GA non-dominant AG non-dominant AG dominant AG waist α (95%CI) 1.812 (1.689 to 1.936) 1.938 (1.815 to 2.060) 1.883 (1.766 to 2.001) 1.514 (1.418 to 1.610) β (95%CI) 0.011 (0.010 to 0.012) 0.012 (0.011 to 0.013) 0.011 (0.010 to 0.012) 0.020 (0.019 to 0.021) MET 1.812 + 0.011 mg 1.938 + 0.012 mg 1.883 + 0.011 mg 1.514 + 0.020 mg Adjusted R2 76.1 73.7 74.0 84.2 α (95%CI) 1.898 (1.767 to 2.030) 2.032 (1.900 to 2.163) 2.012 (1.885 to 2.139) 1.533 (1.428 to 1.638) β (95%CI) 0.011 (0.010 to 0.012) 0.011 (0.010 to 0.012) 0.010 (0.009 to 0.011) 0.020 (0.019 to 0.021) MET 1.898+ 0.011 mg 2.032 + 0.011mg 2.012 + 0.010 mg 1.533 + 0.020 mg Adjusted R2 80.4 78.3 77.9 86.4 α (95%CI) 1.260 (1.152 to 1.368) 1.363 (1.256 to 1.471) 1.351 (1.242 to 1.461) 1.117 (1.010 to 1.224) β1 (95%CI) 0.020 (0.019 to 0.021) 0.022 (0.021 to 0.023) 0.020 (0.019 to 0.021) 0.031 (0.029 to 0.032) β2 (95%CI) x10-5 -1.1 (-1.2 to -1.0) -1.4 (-1.5 to -1.3) -1.2 (-1.3 to -1.1) -2.6 (-2.9 to -2.2) MET 1.260 + 0.020 mg + (-1.1 mg2 x 10-5) 1.363 + 0.022 mg + (-1.4 mg2 x 10-5) 1.351 + 0.020 mg + (-1.2 mg2 x 10-5) 1.117 + 0.031 mg + (-2.6 mg2 x 10-5) Adjusted R2 89.8 88.8 87.6 89.5 Equation 1: only outputs from 8 activities were included (similar activities used by ▇▇▇▇▇▇▇▇▇▇ et al); Equation 2: 9 activities were included (▇▇▇▇▇▇▇▇▇▇ + intermittent running) Equation 3: Equation 2 and inclusion of a quadratic term for acceleration. Figures presented in the main document were based on this equation.
View Source

Examples of Supplementary Table in a sentence

  • Eleven SNPs in CSA and CSB were significantly associated with chromatid breaks per cell (P values = 0.004-0.039; Table 3; Supplementary Table S1).8 Among these 11 SNPs, the minor alleles of two SNPs were associated with an increase in mean number of breaks 8 Supplementary material for this article is available at Cancer Epidemiology, Biomakers and Prevention Online (▇▇▇▇://▇▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇/).

  • Nor was there a clear tendency for inter-observer agreement for discrete variables to depend on the time between the scans (Supplementary Table S1).

  • During SNP QC, we removed ambiguous SNPs (A/T or C/G SNPs with MAF > 0.49) and rare variants with MAF < 0.005; we only retained SNPs with high imputation quality (imputation information score > 0.4) (Supplementary Table 1).

  • Using data from the Exome Aggregation Consortium (ExAC) browser and a local dataset of 15,000 exomes, we found evidence of a possible frequency of bial- lelic pathogenic SELENBP1 mutations of approximately 1:90,000, corresponding to a carrier frequency of 1 per 300 individuals (Supplementary Note and Supplementary Table 1).

  • Post-TRIPOD, the number of studies that included predictors based on significance levels in univariable analysis decreased (pre-TRIPOD: 67%, post-TRIPOD: 44%, Figure 2 and Supplementary Table 8) as well as the number of studies using stepwise methods to retain pre- dictors (pre-TRIPOD: 63%, post-TRIPOD: 48%).

  • However, in both eras some studies still reported no information at all on the final model (pre-TRIPOD 8%; post-TRIPOD 4%, Figure 3 and Supplementary Table 8).

  • An improvement TRIPOD statement: a preliminary pre-post analysis of reporting and methods of prediction models for 16 of the individual TRIPOD items (44% of items, Supplementary Table 2) was seen, while 3 (8%) of items showed no improvement and 17 (47%) items showed a decrease in the percentage of articles appropriately reporting the item.

  • The detailed annotations and data for these genes are presented in Supplementary Table 1.

  • Using the 2018 TRIPOD Adherence assessment form, a minimal non-significant increase in the overall percentage of reported items was found comparing the pre-TRIPOD period (74%) with the post-TRIPOD period (76%, absolute difference 2%, 95% CI: -4% to 7%, Figure 2, Supplementary Table 1), with no clear trend over the years (Supplementary Figure 1).

  • Most external validation studies performed the validation in individuals fully unrelated to the development cohort (pre-TRIPOD 78%, post-TRIPOD: 88%, Figure 3 and Supplementary Table 9).


More Definitions of Supplementary Table

Supplementary Table. 1: Risk of bias analysis
View Source
Supplementary Table. 6: Average confusion matrix indicating the ability of thresholds to accurately classify intensities (% accurately classified). Columns indicate actual intensity, while rows indicate predicted intensity. Sedentary a n (%) Light b n (%) Moderate n (%) Vigorous n (%) Kappa (SE) GA non-dominant 0.63 (0.02) Sedentary 151 (58.8) 104 (40.5) 2 (0.8) 0 (0.0) Light 2 (2.2) 70 (70.1) 20 (21.7) 0 (0.0) Moderate 0 (0.0) 6 (4.1) 117 (80.7) 22 (15.2) Vigorous 0 (0.0) 0 (0.0) 18 (13.2) 118 (86.7) AG non-dominant 0.72 (0.02) Sedentary 144 (77.4) 42 (22.6) 0 (0.0) 0 (0.0) Light 21 (10.9) 146 (75.7) 26 (13.5) 0 (0.0) Moderate 0 (0.0) 10 (5.8) 130 (75.1) 33 (19.1) Vigorous 0 (0.0) 0 (0.0) 14 (10.1) 125 (89.9) AG dominant 0.66 (0.02) Sedentary 171 (65.5) 88 (33.7) 2 (0.8) 0 (0.0) Light 11 (7.1) 116 (74.4) 29 (18.6) 0 (0.0) Moderate 0 (0.0) 11 (6.0) 138 (75.0) 35 (19.0) Vigorous 0 (0.0) 0 (0.0) 17 (11.0) 138 (89.0) AG waist 0.53 (0.02) Sedentary 185 (51.8) 171 (47.9) 1 (0.3) 0 (0.0) Light 1 (2.6) 23 (60.5) 14 (36.8) 0 (0.0) Moderate 0 (0.0) 26 (12.8) 146 (71.6) 32 (15.7) Vigorous 0 (0.0) 0 (0.0) 27 (15.7) 145 (84.3)
View Source

Related to Supplementary Table

  • Supplementary Card means a Card issued by the Bank subject to this Agreement to a Supplementary Cardholder nominated by the Principal Cardholder and at the joint request of the Principal Cardholder and such Supplementary Cardholder; and

  • 2001 CSO Mortality Table means that mortality table, consisting of separate rates of mortality for male and female lives, developed by the American Academy of Actuaries CSO Task Force from the valuation basic mortality table developed by the Society of Actuaries Individual Life Insurance Valuation Mortal- ity Task Force, and adopted by the NAIC in December 2002. The 2001 CSO mortality table is included in the Proceedings of the NAIC (2nd Quarter 2002) and is supplemented by the 2001 CSO preferred class structure mortality table and may be obtained from the office. Unless the context indicates otherwise, the “2001 CSO mortality table” includes both the ultimate form of that table and the select and ultimate form of that table and includes both the smoker and nonsmoker mortality tables and the composite mor- tality tables. It also includes both the age−nearest−birthday and age−last−birthday bases of the mortality tables.

  • Composite mortality tables means mortality tables with rates of mortality that do not distinguish between smokers and nonsmokers.

  • Supplementary Material means, collectively, any amendment to the Final Prospectus, any amendment or supplemental prospectus or ancillary materials that may be filed by or on behalf of the Corporation under the Securities Laws relating to the distribution of the Securities hereunder;

  • Supplementary Conditions means the part of the Contract that amends or supplements the General Conditions;